Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist

Journal of Peptide Research

Volumn 65, Issue 3, 2005, Pages 322-332

  Bennett, M A ^a,d   Murray, T F ^b   Aldrich, Jane V ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

Dynorphin A analogs; Inverse agonists; Kappa opioid receptors; Opioid peptides; Peptide antagonists

Indexed keywords

ADENYLATE CYCLASE; ALANINE; ARGININE; ARODYN; ARODYN[1 N METHYLPHENYLALANINE 2,3 PHENYLALANINE 4 ARGININE 8 DEXTRO ALANINE]; ARODYN[1 TYROSINE 2,3 PHENYLALANINE 4 ARGININE 8 DEXTRO ALANINE]; ARODYN[1,2,3 PHENYLALANINE 4 ARGININE 8 DEXTRO ALANINE 10 ALANINE]; DEXTRO AMINO ACID; DYNORPHIN A; DYNORPHIN A DERIVATIVE; DYNORPHIN[1-13]; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; LYSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; BINDING AFFINITY; CHO CELL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACETYLATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ASSAY; GENE EXPRESSION; ISOMER; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALANINE; AMINO ACID SUBSTITUTION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DYNORPHINS; PEPTIDES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 16444386247     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3011.2005.00216.x     Document Type: Conference Paper

References (40)

1. Bennett, M.A., Murray, T.F. & Aldrich, J.V. (2001) Structure-activity relationships of arodyn, a novel dynorphin A (1-11) analogue. In: Peptides: Wave of the Future (Lebl, M. & Houghten, R.A., eds), pp. 894-895, American Peptide Society, San Diego, CA.
2. Aldrich, J.V. & Vigil-Cruz, S. (2003) Narcotic analgesics. In: Burger's Medicinal Chemistry and Drug Discovery, Vol. 6 (Abraham, D., ed.), pp. 329-481. John Wiley & Sons, Inc., New York, NY.
3. Rothman, R.B., Gorelick, D.A., Heishman, S.J., Eichmiller, P.R., Hill, B.H., Norbeck, J. & Liberto, J. (2000) An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence. J. Substance Abuse Treat. 18, 277-281.
4. Mague, S.D., Pliakas, A.M., Todtenkopf, M.S., Tomasiewicz, H.C., Zhang, Y., Stevens, W.C. Jr, Jones, R.M., Portoghese, P.S. & Carlezon, W.A. Jr (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323-330.
5. Portoghese, P.S., Nagase, H. & Takemori, A.E. (1987) Binaltorphimine and norbinaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40, 1287-1292.
6. Ko, M.C.H., Johnson, M.D., Butelman, E.R., Willmont, K.J., Mosberg, H.I. & Woods, J.H. (1999) Intracisternal nor-binaltorphimine distinguishes central and peripheral κ-opioid antinociception in rhesus monkeys. J. Pharmacol. Exp. Ther. 191, 1113-1120.
7. Stevens, W.C. Jr, Jones, R.M., Subramanian, G., Metzger, T.G., Ferguson, D.M. & Portoghese, P.S. (2000) Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J. Med. Chem. 43, 2759-2769.
8. Jones, R.M. & Portoghese, P.S. (2000) 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur. J. Pharmacol. 396, 49-52.
9. 303E] opioid receptors. J. Med. Chem. 41, 4911-4914.
10. Negus, S.S., Mello, N.K., Linsenmayer, D.C., Jones, R.M. & Portoghese, P.S. (2002) Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology 163, 412-419.
11. 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J. Med. Chem. 44, 1687-2690.
12. 4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl] methyl-2-methylpropyl)-1,2,3,4-tetrahydio-3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. J. Med. Chem. 46, 3127-3137.
13. Thomas, J.B., Fix, S.E., Rothman, R.B., Mascarella, S.W., Dersch, C.M., Cantrell, B.E., Zimmerman, D.M. & Carroll, F.I. (2004) Importance of phenolic address groups in opioid kappa receptor selective antagonists. J. Med. Chem. 47, 1070-1073.
14. Wang, J.B., Johnson, P.S., Wu, J.M., Wang, W.F. & Uhl, G.R. (1994) Human κ opiate receptor second extracellular loop elevates dynorphin's affinity for human μ/κ chimeras. J. Biol. Chem. 269, 25966-25969.
15. Xue, J.-C., Chen, C., Zhu, J., Kunapuli, S., DeRiel, J.K., Yu, L. & Liu-Chen, L.-Y. (1994) Differential binding domains of peptide and non-peptide ligands in the cloned rat κ opioid receptor. J. Biol. Chem. 169, 30195-30199.
16. Meng, F., Hoversten, M.T., Thompson, R.C., Taylor, L., Watson, S.J. & Akil, H. (1995) A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ opioid receptors: potential role of extracellular domains. J. Biol. Chem. 170, 12730-12736.
17. Paterlini, G., Portoghese, P.S. & Perguson, D.M. (1997) Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the κ-opioid receptor. A model for activation. J. Med. Chem. 40, 3254-3262.
18. Ferguson, D.M., Kramer, S., Metzger, T.G., Law, P.Y. & Portoghese, P.S. (2000) Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the κ-opioid receptor does not affect dynorphin A(1-13) affinity and function. J. Med. Chem. 43, 1251-1252.
19. Wan, Q., Murray, T.F. & Aldrich, J.V. (1999) A novel acetylated analogue of dynorphin A-(1-11) amide as a κ-opioid receptor antagonist. J. Med. Chem. 42, 3011-3013.
20. Chavkin, C. & Goldstein, A. (1981) Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl. Acad. Sci. USA 78, 6543-6547.
21. Schwyzer, R. (1977) ACTH: A short introductory review. Ann. NY Acad. Sci. 197, 3-16.
22. 2: A dynorphin analogue with high selectivity for the κ opioid receptor. J. Med. Chem. 43, 2698-2702.
23. 2 analogues lacking an N-terminal amino group: Potent and selective κ opioid antagonists. J. Med. Chem. 44, 3048-3053.
24. Dooley, C.T., Chung, N.N., Schiller, P.W. & Houghten, R.A. (1993) Acetalins: opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries. Proc. Natl. Acad. Sci. USA 90, 10811-10815.
25. Choi, H. (1995) Synthesis and biological evaluation of dynorphin A analogues as pharmacological probes of opioid receptors, PhD Thesis, Oregon State University, Corvallis, pp. 135-153.
26. Kulkarni, S.N., Choi, H., Murray, T.F., DeLander, G.E. & Aldrich, J.V. (1996) The use of the message-address concept in the design of potential antagonists based on dynorphin A. In: Peptides: Chemistry, Structure and Biology (Kaumaya, T.P. & Hodges, R.S., eds), pp. 655-656, Mayflower Scientific Ltd., West Midlands, UK.
27. Aldrich, J.V., Wan, Q. & Murray, T.F. (2000) Identification of Novel Kappa Opioid Receptor Selective Peptides from a Combinatorial Library. Pacifichem 2000, Honolulu, HI.
28. Bennett, M.A., Murray, T.F. & Aldrich, J.V. (2002) Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist. J. Med. Chem. 45, 5617-5619.
29. Vig, B.S. & Aldrich, J.V. (2003) An inexpensive, manually operated, solid-phase, parallel synthesizer. Aldrichimica Acta 37, 2.
30. Carpino, L.A., El-Faham, A., Minor, C.A. & Albericio, F. (1994) Advantageous application of azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide synthesis. J. Chem. Soc., Chem. Comm, 101-103.
31. Kaiser, E., Colescott, R.L., Bossinger, C.D. & Cook, P.L. (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem 34, 595-598.
32. Vojkovsky, T. (1995) Detection of secondary amines on solid phase. Pept. Res. 8, 236-237.
33. 8]-dynorphin A. J. Org. Chem. 57, 5599-5403.
34. Arttamangkul, S., Ishmael, J.E., Murray, T.F., Grandy, D.K., DeLander, G.E., Kieffer, B.L. & Aldrich, I.V. (1997) Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence. J. Med. Chem. 40, 1211-1218.
35. 50] of an enzymatic reaction. Biochem. Pharmacol. 11, 3099-3108.
36. 10]dynorphin A-(1-11) are high affinity partial agonists at the cloned rat κ-opioid receptor. Eur. J. Pharmacol. 338, 191-197.
37. Snyder, K.R., Story, S.C., Heidt, M.E., Murray, T.F., DeLander, G.E. & Aldrich, J.V. (1992) Effect of modification of the basic residues of dynorphin A-(1-13] amide on κ opioid receptor selectivity and opioid activity. J. Med. Chem. 35, 4330-4333.
38. Turcotte, A., Lalonde, J.-M., St-Pierre, S. & Lemaire, S. (1984) Dynorphin-(1-13) I. Structure-function relationships of Ala-containing analogs. Int. J. Pept. Protein Res. 13, 361-367.
39. Kawasaki, A.M., Knapp, R.J., Walton, A., Wire, W.S., Zalewska, T., Yamamura, H.I., Porreca, F., Burks, T.F. & Hruby, V.J. (1993) Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10. Int. J. Pept. Protein Res. 41, 411-419.
40. Becker, J.A.J., Wallace, A., Garzon, A., Ingallinella, P., Bianchi, E., Cortese, R., Simonin, F., Kieffer, B.L. & Pessi, A. (1999) Ligands for κ-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J. Biol Chem. 274, 27513-27522.